Gregory Stea

Mr. Stea is a pharmaceutical executive with over 30 years of experience in sales and commercial operations. From 2009 to 2015, he served as Senior Vice President of Commercial Operations for Cubist, which was acquired by Merck in 2015 for $9.5 billion. In this role, Mr. Stea was responsible for leading all commercial operations, including the launch and sales of Cubicin, Zerbaxa and Sivextro. During this time he was also a member of the Cubist Operating Committee which was responsible for the company’s overall strategy. Mr. Stea served in other leadership roles at Cubist from 2002 to 2009 and at Amgen, where he was the first employee of its sales organization in 1988. Mr. Stea earned his Bachelor’s Degree in Business Administration from Temple University and completed the University of Michigan’s Executive Education program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology. He most recently served as an advisor to La Jolla Pharmaceutical Company in preparing for commercialization of their first drug, Angiotensin II (Giapreza), and he currently serves on the Board of Directors of Achaogen.